These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Antibody-based vaccines for the treatment of melanoma. Lutzky J; Gonzalez-Angulo AM; Orzano JA Semin Oncol; 2002 Oct; 29(5):462-70. PubMed ID: 12407511 [TBL] [Abstract][Full Text] [Related]
44. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Miller K; Abeles G; Oratz R; Zeleniuch-Jacquotte A; Cui J; Roses DF; Harris MN; Bystryn JC Cancer; 1995 Jan; 75(2):495-502. PubMed ID: 7812920 [TBL] [Abstract][Full Text] [Related]
45. Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine. Shrayer D; Kouttab N; Maizel A; Wanebo H; Hearing VJ; Gersten DM Int J Cancer; 1993 Feb; 53(4):696-702. PubMed ID: 8436442 [TBL] [Abstract][Full Text] [Related]
46. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice. Johnston D; Bystryn JC Cancer Immunol Immunother; 2005 Apr; 54(4):345-50. PubMed ID: 15692845 [TBL] [Abstract][Full Text] [Related]
47. Immunogenicity and cross-protection among B16 melanoma variants with differing proclivities to metastasize. Harte PJ; Steele G; Munroe AE; Rayner AA; Wang BS; Wilson RE; Mannick JA J Surg Oncol; 1981; 18(4):381-8. PubMed ID: 7321567 [TBL] [Abstract][Full Text] [Related]
48. B700 antigen as a component of an antimelanoma vaccine: formalinized extracellular antigens. Shrayer D; Gersten DM; Koness J; Maizel A; Wanebo H; Hearing VJ Pigment Cell Res; 1992 Sep; 5(3):107-12. PubMed ID: 1409447 [TBL] [Abstract][Full Text] [Related]
49. Characterization of immunologically significant unique B16 melanoma proteins produced in vivo and in vitro. Gersten DM; Hearing VJ; Marchalonis JJ Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5109-12. PubMed ID: 6946458 [TBL] [Abstract][Full Text] [Related]
51. Effective pressure and treatment duration of high hydrostatic pressure to prepare melanoma vaccines. Liu K; Yan S; Ma Z; Liu B Oncol Lett; 2020 Aug; 20(2):1135-1142. PubMed ID: 32724353 [TBL] [Abstract][Full Text] [Related]
52. [Delayed hypersensitivity and its clinical application--malignant melanoma]. Ishihara K Nihon Hifuka Gakkai Zasshi; 1975 Mar; 85(3):130-1. PubMed ID: 1079276 [No Abstract] [Full Text] [Related]
53. Advanced Oxidation Nanoprocessing Boosts Immunogenicity of Whole Tumor Cells. Zhang M; Huang Y; Zou J; Yang Y; Yao Y; Cheng G; Yang Y Adv Sci (Weinh); 2023 Aug; 10(22):e2302250. PubMed ID: 37211712 [TBL] [Abstract][Full Text] [Related]
54. Targeting the tumor mutanome for personalized vaccination therapy. Kreiter S; Castle JC; Türeci O; Sahin U Oncoimmunology; 2012 Aug; 1(5):768-769. PubMed ID: 22934277 [TBL] [Abstract][Full Text] [Related]
55. Spontaneous regression of cancer and the importance of finding its cause. Cole WH Natl Cancer Inst Monogr; 1976 Nov; 44():5-9. PubMed ID: 799760 [TBL] [Abstract][Full Text] [Related]
56. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Wilson BS; Lloyd RV Am J Pathol; 1984 Jun; 115(3):458-68. PubMed ID: 6375394 [TBL] [Abstract][Full Text] [Related]
57. Lysis and growth stimulation of a murine melanoma determined by density of macrophage populations. Leibovici J; Hoenig S Anticancer Res; 1985; 5(5):545-51. PubMed ID: 4062257 [TBL] [Abstract][Full Text] [Related]